The effect of phosphomycin on the continuation of treatment with carbapenems in urinary tract infections caused by Enterobacteriaceae of extended-spectrum beta-lactamase after discharge

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191104045328N3

Enrollment

105

Registered

2020-02-01

Start date

2019-12-06

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urinary tract infections caused by Enterobacteriaceae of extended-spectrum beta-lactamase. Urinary tract infection, site not specified

Interventions

Intervention 1: Intervention group: Thirty-five patients will receive carbapenem 1 g intravenously three times daily for 7 days and then oral phosphomycin treatment for 7 days in a 3-gram sachet (outp

Eligibility

Sex/Gender

All

Age

19 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with ESBL urinary tract infection admitted to the infectious ward of Vali Asr Hospital

Exclusion criteria

Exclusion criteria: Kidney Failure or Cr > 2 Immune deficiency disease such as transplants and AIDS Chemotherapy or leukemia or any type of cancer Drug sensitivity

Design outcomes

Primary

Measure	Time frame
The result of urine culture. Timepoint: One week after treatment. Method of measurement: Urine culture.;Urinary symptoms. Timepoint: After the course of treatment. Method of measurement: Patient visit.;Urine sample analysis. Timepoint: After the course of treatment. Method of measurement: urine analysis test.;Leukocytosis. Timepoint: After the course of treatment. Method of measurement: Complete blood count.	—

Measure

Time frame

The result of urine culture. Timepoint: One week after treatment. Method of measurement: Urine culture.;Urinary symptoms. Timepoint: After the course of treatment. Method of measurement: Patient visit.;Urine sample analysis. Timepoint: After the course of treatment. Method of measurement: urine analysis test.;Leukocytosis. Timepoint: After the course of treatment. Method of measurement: Complete blood count.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Masoomeh Soufian

Arak University of Medical Sciences

ma_sofian@yahoo.com+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026